High Dose Oral 4-Aminosalicylic Acid (PASER�) to Control Acute Flares of Mild to Moderate Crohn's Disease
Information source: Jacobus Pharmaceutical
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Crohn's Disease
Intervention: 4-Aminosalicylic acid (Drug); PASER placebo granules (Drug)
Phase: Phase 2
Status: Terminated
Sponsored by: Jacobus Pharmaceutical Official(s) and/or principal investigator(s): David P. Jacobus, MD, Study Chair, Affiliation: Jacobus Pharmaceutical Kathy L. Ales, MD, Study Director, Affiliation: Jacobus Pharmaceutical Daniel Present, MD, Principal Investigator, Affiliation: Icahn School of Medicine at Mount Sinai Stephen B. Hanauer, MD, Principal Investigator, Affiliation: University of Chicago Hospitals John Hanson, MD, Principal Investigator, Affiliation: Charlotte Gastroenterology & Hepatology, PLLC Iris Dotan, MD, Principal Investigator, Affiliation: Tel-Aviv Sourasky Medical Center Rami Eliakim, MD, Principal Investigator, Affiliation: Rambam Health Care Campus
Summary
The purpose of this 4 week study is to determine whether PASER®, an approved delayed-release
oral formulation of 4-aminosalicylic acid, in doses of 4 grams three times daily for 2 weeks
followed by 4 grams twice daily for 2 weeks, will resolve an acute flare of ileocecal
Crohn's disease.
Clinical Details
Official title: A Prospective Randomized Double-Blind Study of PASER® in the Management of Patients Experiencing an Acute Flare of Crohn's Disease
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Response, as defined by a reduction of the CDAI score of >70 points by 4 weeks compared with baseline
Secondary outcome: Rate of remission as defined by the decrease in CDAI > 100 points and total CDAI < 150 by 4 weeksRate of response as defined by a reduction in HBI to less than 5 by 4 weeks Rate of remission as defined by the decrease in HBI to less than 3 by 4 weeks Time to response and/or remission including time to change in HBI, according to elements of the daily patient diary Increase in IBDQ to greater than 170 and the time to score above 170 The change from baseline in the patient's general sense of disease activity as recorded in the individual daily diary Absence of night time stools, if they were present on entry, and time to disappearance Time to normalization of all other components in the diary Change in Hgb, ESR, CRP, platelet count, calprotectin from baseline and time to normalization Change in global physician assessment of disease activity from baseline to study completion
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Age 18-65
- Crohn's disease involving predominantly the ileum and/or cecum. The diagnosis must
have been established by radiography, endoscopy and/or biopsy (at least 2 of the 3
modalities) with at least one confirmatory test having been performed no more than 36
months before entry. The diagnosis must have been confirmed by at least one
gastroenterologist.
- Harvey Bradshaw Index of at least 7
- The onset of the acute flare should have been abrupt, declaring itself over 72 hours,
and should have started no more than 4 weeks before study entry. Symptoms relating
to the flare should not have diminished or started to improve prior to entry.
- Written informed consent
Exclusion Criteria:
- Concomitant corticosteroids, including budesonide
- Corticosteroids within the previous 2 months
- Cyclosporine, mycophenolate mofetil or experimental drugs during the last three
months
- Maintenance infliximab, or infliximab or other biologics in the preceding 3 months
- Change in dose during previous 4 weeks in 5-aminosalicylate, probiotic and/or
antibiotic, or in chronic azathioprine, 6-mercaptopurine, or methotrexate
- If currently using azathioprine, 6-mercaptopurine or methotrexate, these must have
been used steadily for at least 4 months
- Current experimental drugs or experimental drugs within the last 3 months
- If the severity of the flare has started to decrease spontaneously
- Coexisting diagnosis of primary sclerosing cholangitis,
- Infectious diarrhea,
- Signs of intestinal obstruction or perforation or abscess,
- New fistulization as part of the acute flare or increased activity in chronic
fistula(e) as part of the acute flare,
- Increased activity of pre-existing anal or rectal Crohn's disease as part of the
flare
- Allergy or sensitivity to salicylates
- Pregnancy or breast-feeding
- Failure of a woman of child-bearing age to agree to use adequate contraception for
the 4 week period of the trial, if sexually active
- Severe renal or hepatic disease
Locations and Contacts
Rambam Medical Center, Haifa 31096, Israel
Tel-Aviv Sourasky Medical Center, Tel-Aviv 64239, Israel
The University of Chicago, Chicago, Illinois 60637, United States
Mount Sinai School of Medicine IBD Research Center, New York, New York 10028, United States
Charlotte Gastroenterology and Hepatology, PLLC, Charlotte, North Carolina 28207, United States
Additional Information
Starting date: January 2007
Last updated: October 14, 2008
|